🇺🇸 GLIMEPIRIDE + METFORMIN in United States

113 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Glucose Increased — 18 reports (15.93%)
  2. Off Label Use — 14 reports (12.39%)
  3. Drug Ineffective — 13 reports (11.5%)
  4. Asthenia — 11 reports (9.73%)
  5. Fatigue — 11 reports (9.73%)
  6. Dizziness — 10 reports (8.85%)
  7. Hypoglycaemia — 9 reports (7.96%)
  8. Pain In Extremity — 9 reports (7.96%)
  9. Pyrexia — 9 reports (7.96%)
  10. Weight Decreased — 9 reports (7.96%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is GLIMEPIRIDE + METFORMIN approved in United States?

GLIMEPIRIDE + METFORMIN does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for GLIMEPIRIDE + METFORMIN in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.